Close

Acceleron Pharma discontinues development of muscular dystrophy drug

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

The clinical-stage biopharmaceutical company Acceleron Pharma Inc. has announced the discontinuation of the development of drug for facioscapulohumeral muscular dystrophy (FSHD), ACE-083. Further clinical trials will not be conducted in this arena as the drug could not achieve statistically significant improvements in functional endpoints relative to placebo in a Phase II trial.

The drug indicated an increase in mean total muscle volume but failed to convert to statistically significant improvements in functional tests. As expected Acceleron Pharma was disappointed with the way things had gone as it always stated that ACE-083 would prove to be an important new therapy for patients with FSHD, a genetic muscular disorder where muscles of the face, shoulder blades and upper arms are among the most affected.

Habib Dable, President and chief executive officer of Acceleron expressed his disappointment and said that the data showed no evidence to support further development of ACE-083. The company, however, is looking forward to the first quarter of the next year as it is expecting top-line results from the placebo-controlled Phase II trial of ACE-083 in patients having Charcot-Marie-Tooth disease which is a neuromuscular disorder of different pathophysiology.

Latest stories